Andy: NVX has alot going with the meningitis conjugate vaccines at the Phase I and II stage. It is my understanding that NVX does have a Phase II Group C study going on now with infants in England.
In the next year or so we will be hearing alot more about their meningitis actyivities I am sure.
Meanwhile we focus on CERTIVA approval.
And then we follow the CERTIVA/ SAFETY campaign.
Let's put it this way . If the Company doesn't run one , I will.
One only need go back to the Company release of Oct.23 '97
nava.com
Here is the lead off statement: <<<< " Beltsville, MD, October 23, 1997 - North American Vaccine, Inc. (AMEX:NVX) today announced that
promising results from a Swedish Mass Vaccination Project using its monocomponent acellular pertussis
vaccine are being presented to the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers
for Disease Control (CDC). The data reveals that within the first year following the start of this project, the
incidence of pertussis infection in G”teborg, Sweden decreased dramatically along with a substantial reduction
in hospitalizations of infants due to complications from pertussis. Moreover, none of the infants and children
participating in the project experienced any serious vaccine-related adverse reactions following more than
120,000 injections." >>>>>>>>>>>
Now I can tell you that this last statement cannot be made about the infamous Swedish II trials conducted by the competition . The SAFETY results in that study were not pretty so I don't expect we'll be reading much about it.
I consider this as certainly one main reason why NVX was asked to present the results of this massive post marketing study on SAFETY to the CDC/ACIP.
I should add here that as investors we all are aware of this study thru the news release of Oct 23 but i can tell you that the medical profession, with the exception of a few who attended a medical conference in Canada, have never heard of CERTIVA or NVX. If you doubt that ask your pediatrician. Earlier post right on this thread also confirm this point.
I think we can assume that a paper on this study will be published very soon and there will be alot more information coming out that will further support CERTIVA.
NVX/Abbott/ the Swedes/ the Danes/Chiron,Behring/and OTHERS, do have a very compelling story to tell.
I DO THINK CERTIVA WILL BE VERY WELL RECEIVED IN THE MARKETPLACE. NVX JUST HAS A HELL OF A LOT GOING FOR THEM. I'll have a lot more to say about this after CERTIVA gets FDA approval.
If you happen to be SHORT and your underlying reason is that NVX won't live up to expectations in the marketplace, I'd say that you are in BIG TROUBLE and TIME is on the side of NVX.
:-} |
